News

The researchers discovered that, when a molecule responsible for dialing down the immune system malfunctions in the brain cells of mice, the rodents develop symptoms of Alzheimer’s disease.

OP-145 is designed to break the recurring cycle of infection causing chronic middle ear infection and is currently in phase II trials. After successful completion of this trial,

The waiting period is a requirement under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Termination of the waiting period satisfies a closing condition of the merger agreement between

This decision follows another decision by Roche earlier this year to discontinue its involvement in the co-development of daclizumab for the treatment of asthma. The co-development agreement between

The three-year agreement provides the Austrian Ministry of Health with future access to the company’s cell-based vaccine production capacity in the event of an avian flu pandemic. Baxter

The acquisition will create a large biopharmaceutical company with revenue of more than $4.23 billion and annual research and development investment of $986.91 million. In November, the executive

The trial results have been sent to the Chinese State Food and Drug Administration (SFDA) and the company anticipates an approval response from the SFDA in the second

As part of the settlement, Teva will pay up to $70 million to Pfizer. Teva was also provided with the option to sell its own generic version of

The FDA orphan drug designation is specifically for pneumocystis jiroveci pneumonia (PCP), a common life-threatening opportunistic infection in HIV/AIDS and other immunosuppressed patients. The designation provides Immtech with